Galapagos has announced its intention to wind down its cell therapy business, following a comprehensive review of strategic alternatives, including a potential divestiture.  The move follows similar ones by Novo Nordisk and Takeda, which recently announced the decision to discontinue its cell therapy efforts, as part of a “strategic portfolio prioritisation process”.    “We have undertaken […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!